Eli Lilly (LLY) Q3 FY25 earnings call

Eli Lilly delivered a robust Q3 FY25, driven by exceptional growth in key products like Mounjaro and Zepbound, leading to a significant revenue and EPS guidance raise. The company continues to advance its pipeline with multiple positive Phase III readouts for orforglipron and other assets, alongside strategic manufacturing expansions to support future launches. Management is focused on expanding market access and addressing unmet medical needs globally, leveraging both traditional and direct-to-consumer channels.